跳至主要内容
临床试验/NCT00571727
NCT00571727已完成2 期

A Study of Long-Term Human Recombinant Insulin-Like Growth Factor-1 (rhIGF-1) in Children With Short Stature Due to Growth Hormone Insensitivity Syndrome (GHIS)

Ipsen1 个研究点 分布在 1 个国家目标入组 92 人开始时间: 1991年5月20日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
Ipsen
入组人数
92
试验地点
1
主要终点
Annualized Height Velocity Up to 12 Years

研究概览

简要总结

The objective of this study was to evaluate the long-term safety and effectiveness of mecasermin (the study drug) in children with growth failure due to severe Primary insulin-like growth factor-1 deficiency (Primary IGFD).

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
2 Years 至 21 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Height <-2SD for age and gender
  • IGF-1 <-2SD for age and gender
  • Evidence of GH resistance

排除标准

  • closed epiphyses
  • prior active malignancy
  • major organ disfunction
  • treatment with medications that would diminish growth
  • clinically significant cardiac abnormalities

研究组 & 干预措施

mecasermin, injections BID of rhIGF-1

Experimental

干预措施: mecasermin (Drug)

结局指标

主要结局

Annualized Height Velocity Up to 12 Years

时间窗: Baseline (Pre-dose) and up to 12 years

Height velocity is the difference between 2 height measurements, divided by years elapsed between measurements.

Number of Naive Participants With Height Velocity <5 cm/y at the End of 1 Year of Study Treatment

时间窗: Baseline (Pre-dose) and 1 year

Height measurements were performed using wall-mounted stadiometers for analysis of growth data.

次要结局

  • Approximate Increase in Height Over Expected for Naïve Participants With Near-Adult Height(Baseline (Pre-dose) and up to 19 years)
  • Height Velocity Standard Deviation Score Up to 12 Years(Baseline (Pre-dose) and up to 12 years)
  • Height Standard Deviation Score Up to 12 Years(Baseline (Pre-dose) and up to 12 years)

研究者

发起方
Ipsen
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Long-Term Treatment With rhIGF-1 in GHIS | 临床试验